Switch theme
Sign up to access all valuation multiples
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
1999
1.3K+
LTM Revenue $394M
LTM EBITDA -$883M
$12.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Insmed has a last 12-month revenue of $394M and a last 12-month EBITDA of -$883M.
In the most recent fiscal year, Insmed achieved revenue of $364M and an EBITDA of -$819M.
Insmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Insmed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $305M | $364M | XXX | XXX | XXX |
| Gross Profit | $190M | $240M | XXX | XXX | XXX |
| Gross Margin | 62% | 66% | XXX | XXX | XXX |
| EBITDA | -$660M | -$819M | XXX | XXX | XXX |
| EBITDA Margin | -216% | -225% | XXX | XXX | XXX |
| Net Profit | -$482M | -$750M | XXX | XXX | XXX |
| Net Margin | -158% | -206% | XXX | XXX | XXX |
| Net Debt | $51.2M | $673M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Insmed's stock price is $71.
Insmed has current market cap of $12.9B, and EV of $12.6B.
See Insmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.6B | $12.9B | XXX | XXX | XXX | XXX | $-5.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Insmed has market cap of $12.9B and EV of $12.6B.
Insmed's trades at 32.0x LTM EV/Revenue multiple, and -14.3x LTM EBITDA.
Analysts estimate Insmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Insmed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $12.6B | XXX | XXX | XXX |
| EV/Revenue | 34.7x | XXX | XXX | XXX |
| EV/EBITDA | -15.4x | XXX | XXX | XXX |
| P/E | -14.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInsmed's NTM/LTM revenue growth is 58%
Insmed's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Insmed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Insmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Insmed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -225% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -167% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 127% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 165% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 293% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Insmed acquired XXX companies to date.
Last acquisition by Insmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Insmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Insmed founded? | Insmed was founded in 1999. |
| Where is Insmed headquartered? | Insmed is headquartered in United States of America. |
| How many employees does Insmed have? | As of today, Insmed has 1.3K+ employees. |
| Who is the CEO of Insmed? | Insmed's CEO is Mr. William H. Lewis, J.D.,M.B.A.. |
| Is Insmed publicy listed? | Yes, Insmed is a public company listed on NAS. |
| What is the stock symbol of Insmed? | Insmed trades under INSM ticker. |
| When did Insmed go public? | Insmed went public in 2000. |
| Who are competitors of Insmed? | Similar companies to Insmed include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Insmed? | Insmed's current market cap is $12.9B |
| What is the current revenue of Insmed? | Insmed's last 12-month revenue is $394M. |
| What is the current EBITDA of Insmed? | Insmed's last 12-month EBITDA is -$883M. |
| What is the current EV/Revenue multiple of Insmed? | Current revenue multiple of Insmed is 32.0x. |
| What is the current EV/EBITDA multiple of Insmed? | Current EBITDA multiple of Insmed is -14.3x. |
| What is the current revenue growth of Insmed? | Insmed revenue growth between 2023 and 2024 was 19%. |
| Is Insmed profitable? | Yes, Insmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
